Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03958201 · ClinicalTrials.gov registry record · Phase 4
Best Management of Muscle Relaxation- Objective Monitoring
A Phase 4 study of Residual Paralysis, Post Anesthesia, sponsored by University of Washington.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT03958201 is a Phase 4 study of Residual Paralysis, Post Anesthesia that has completed, run by University of Washington. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03958201, a Phase 4 study of Residual Paralysis, Post Anesthesia, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate that the investigators can reduce residual paralysis to a very low incidence, and that the investigators can do this while preserving a role for the older and less expensive reversal agent neostigmine. The investigators consider this an evidence-based approach because previous reports clearly indicate that neostigmine is effective for reversal of the most shallow neuromuscular blocks, a level of block now referred to as minimal block. The Investigators also know from previous data that a substantial proportion of patients have minimal block. Sugammadex will be used when the block to be reversed is deeper than minimal, specifically when the objectively measured TOF-ratio is \<40%. The investigators hypothesize that this protocol will be associated with an incidence of residual paralysis of less than 3%. The investigators plan is to study 200 patients.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex
Study Locations (1)
Washington
- Harborview Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-05-28 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03958201
The ClinicalTrials.gov registry entry for NCT03958201 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Residual Paralysis, Post Anesthesia appearing as the primary indexed condition, and to 1 intervention - of which Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex is the first listed.
NCT03958201 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT03958201 about?
NCT03958201 is a clinical study titled "Best Management of Muscle Relaxation- Objective Monitoring". The purpose of this study is to demonstrate that the investigators can reduce residual paralysis to a very low incidence, and that the investigators can do this while preserving a role for the older and less expensive reversal agent neostigmine. The investigators consider this an evidence-based appr...
What is the current status of trial NCT03958201?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2019-05-28. Estimated completion is 2020-03-31.
What conditions does trial NCT03958201 study?
This clinical trial studies the following conditions: Residual Paralysis, Post Anesthesia.
What interventions are being tested in trial NCT03958201?
The interventions under investigation include: Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03958201?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03958201 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.